[Changes in the level of certain hemostatic factors during treatment with lovastatin in patients with primary hyperlipoproteinemia and phenotype IIa and IIb].
12 weeks of hypolipidemic therapy with lovastatin in patients with primary hyperlipoproteinemia phenotype IIa (20 persons) and IIb (10 persons), apart from decrease of serum total cholesterol, LDL-cholesterol and apolipoprotein B concentration caused significant decrease of antithrombin III, plasminogen and Factor VII activity. The mean decrease in antithrombin III activity (from 103.5 to 91.7% in HLP IIa and from 97.3 to 85.4% in HLP IIb) was significant in both groups, decrease of Factor VII activity (from 111.9 to 100.1%) was significant in HLP IIa and decrease of plasminogen (from 101.9 to 90.6%) in HLP IIb. There were no changes in fibrinogen concentration, prothrombin, Factor VIII activity and aPTT during treatment. Significant correlations of changes in blood lipids and changes in hemostatic factors after treatment were observed. The results of this study indicate that changes in blood lipids during hypolipidemic therapy are associated with significant changes in hemostatic factors.
Idzior-Waluś
B
B
Katedry Diagnostyki Biochemicznej, Kliniki Chorób Metabolicznych AM, Krakowie.
D000990:Antithrombin III / Q000378:metabolism*; D005167:Factor VII / Q000378:metabolism*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000378:metabolism; D008148:Lovastatin / Q000627:therapeutic use*; D010641:Phenotype; D010958:Plasminogen / Q000378:metabolism*
D000990:Antithrombin III; D005167:Factor VII; D010958:Plasminogen; D008148:Lovastatin
Zmiany poziomu wybranych czynników układu hemostatycznego w trakcie leczenia lowastatinem pacjentów z hiperlipoproteinemia pierwotna o fenotypie IIa i IIb.